Key result
Review of antithrombotic options for CAD and AFib highlights the rising risk of excess bleeding.
Why the study?
Excess bleeding is a rapidly rising problem when anticoagulation is combined with antiplatelet therapy in patients with coronary artery disease and atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May inform antithrombotic dosing to curb thrombosis while monitoring bleeding; leaves open larger confirmatory trials.
For secondary prevention of coronary artery disease (CAD), oral antiplatelet therapy is essential. In case of coronary intervention, temporary dual antiplatelet therapy is mandatory as well. Recently, low-dose oral anticoagulation has entered the CAD arena. Atrial fibrillation (AF) is often seen in CAD and vice versa. In most patients stroke prevention in AF consists of oral anticoagulation. In many cases of CAD in patients with AF, anticoagulation has to be combined with antiplatelet agents (so called, dual pathway antithrombotic therapy). Excess bleeding in these conditions is a rapidly rising problem. This review addresses the antithrombotic options in CAD alone, in AF alone, and in their combination, when either an invasive or a noninvasive approach has been chosen.
No takes yet. Share an insight, caveat, or question.
Verheugt et al. (2019) conducted a review in Coronary artery disease and atrial fibrillation. Antithrombotics was evaluated. This review summarizes antithrombotic options for patients with coronary artery disease, atrial fibrillation, and their combination, highlighting the rising problem of excess bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: